

LivaNova 2019 Year in Review

committed

Isla
VNS Therapy
Patient,
Drug-Resistant
Epilepsy

For Isla, a Houston 16-year-old, living a normal life seemed impossible because of epilepsy. She was 11 when she had her first seizure, and initially it was so bad she couldn't walk for days at a time. She was missing school and missing out on her social life. VNS Therapy changed that. Today, her seizures come much less often—months instead of days apart—and are much less severe with faster recovery time. These days, she's enrolled in a local college-prep school and excels on her school's drill and dance team.



At LivaNova, we are committed.

We are committed to our direction. To our mission, to our values and to the pillars that guide our strategy. To our employees, to our investors and our communities, and to our future together.

Most importantly, we are committed to patients like Isla and their families, to making a meaningful, lasting difference in their lives with all we do.

Dear Shareholder:

After making significant progress in 2017 and 2018, we began 2019 focused on continuing the momentum of our turnaround. It turned out to be a transitional year. While we had a number of successes, unanticipated market and competitive forces affected our results, particularly in the beginning of the year. We moved quickly to address the challenges, reshaped our business, sharpened our focus and positioned LivaNova to restore momentum. Our 2019 results were impacted, but our commitment to our strategy and our patients was not. Our future is bright, and we are more optimistic than ever about bringing that future to life.

During the year, some areas of continued progress were negatively impacted by unexpected challenges. While our overall Neuromodulation business had another strong year in Europe and Rest of World, a shortfall in our U.S. Epilepsy business required us to reset our short-term expectations. Admittedly painful, this event presented the opportunity to reassess our go-to-market model in this key business and we believe the changes that have been deployed put us in a stronger competitive market position.

Our efforts to change didn't stop with U.S. Epilepsy, as we also made several strategic choices around our portfolio and refined our company's focus on our core growth drivers, margin expansion, cash flow generation and delivering

the new product pipeline. We believe that our sharpened focus positions us very well for 2020 and beyond.

Existing Businesses – Shaping Our Future

U.S. Epilepsy We faced unexpected competitive and distribution challenges in our U.S. Epilepsy business in 2019. Sales in the first quarter were below our expectations and we implemented several immediate responses to stabilize our sales and distribution channel. These efforts enabled us to reverse our performance and show sequential sales gains for the remainder of the year. In addition, we undertook an in-depth review of the business model to better understand the patient journey, enhance our operational effectiveness and improve our go-to-market approach.

Advanced Circulatory Support (ACS) Since the acquisition of TandemLife closed in April 2018, our U.S. ACS business has grown more than 20% for the second year in a row. In July, we received U.S. Food and Drug Administration (FDA) clearance ahead of schedule for LifeSPARC™, our next-generation pump and controller. The new system represents a significant technological upgrade with improved ease of use, more power, better flow rate and greater versatility. All of these features should enable more physicians to adopt ACS therapies within their practice. The launch of LifeSPARC, coupled with the continued traction of our expanded sales force, is expected to further drive 20%-plus growth for our ACS business in 2020 and beyond.

International Markets (Rest of World) In 2019, we delivered double-digit organic growth in the Rest of World region.¹ This performance has been the result of transitioning to a direct distribution model in several key geographies and strengthening our commercial organization for all products. Furthermore, the commercial expansion of Vagus Nerve Stimulation Therapy® (VNS



Therapy) for epilepsy globally resulted in nearly 40% Neuromodulation growth in our Rest of World region in 2019. There are still several large international markets where market access, health system infrastructure and product penetration are low, all of which provide conditions to drive significant growth.

Cardiopulmonary Our Cardiopulmonary business continues to drive strong return on capital for LivaNova and delivered growth in all major product lines in 2019.¹ Cardiopulmonary experienced a stronger than expected first half of the year with favorable capital equipment purchasing patterns, resulting in a solid full-year performance.

Heart Valves Heart Valves had strong sales performance in international markets in 2019, while Perceval sales lagged in the U.S. In November 2019, we announced an initiative to improve the profitability of our Heart Valve business. While focusing commercially on driving Perceval sales growth globally and Mechanical Heart Valve sales growth in Rest of World, we are also accelerating our efforts to optimize fixed cost structure and expenses.

Strategic Portfolio Initiatives and Innovation – Further Driving Growth

Difficult-to-Treat Depression (DTD) Our DTD program had a remarkable year in 2019. In early September, the U.S. Centers for Medicare and Medicaid Services (CMS) accepted our protocol for the RECOVER clinical study, which evaluates VNS Therapy for DTD patients. Under the Coverage with Evidence framework, CMS is providing reimbursement for patients in the RECOVER study, with the possibility of extending it into a larger registry, which could cover thousands of patients. Just three weeks after CMS approved the protocol, we were able to enroll the first patient in the study. This is a testament to the tireless dedication of our clinical investigators and the DTD team, as well as

the significant unmet need in this patient population. After more than a decade of non-coverage from Medicare and commercial insurers despite having FDA approval, we believe the initiation of this Coverage with Evidence study represents a landmark achievement in bringing this life-changing therapy to the millions of patients who suffer from this debilitating disease. In February 2020, we announced an exciting partnership with Verily Life Sciences on the RECOVER study to use its proprietary sensor technologies to explore novel quantitative data measures for assessing the efficacy of DTD treatments.

Heart Failure We remain committed to advancing Autonomic Regulation Therapy (ART) using VNS Therapy to treat heart failure, a condition that affects more than 25 million people worldwide. Since the inception of our ANTHEM-HFrEF pivotal trial, patient enrollment has continued to exceed trial goals, and enrollment recently surpassed 200 patients. In 2019, we presented results from a 60-patient feasibility study, which showed that ART with VNS Therapy delivered improvements in heart failure symptoms with a durable effect.

Obstructive Sleep Apnea Since acquiring ImThera and its hypoglossal nerve stimulation (HGNS) device for the treatment of obstructive sleep apnea, we have been focusing on remediating the system, analyzing the results of the initial THN3 study and determining the best steps to bring this novel device to market as quickly as possible.

Other Progress in 2019

Transcatheter Mitral Valve Replacement (TMVR) In late 2019, we made the difficult decision to discontinue funding for our TMVR program. We were disappointed with the need to end the TMVR program after prolonged efforts to redesign the product to address safety and efficacy concerns. Product design challenges, combined with recent changes in market

2020 Strategy at a Glance



↑
Core Growth
U.S. Epilepsy
U.S. ACS
International

↑
Pipeline Execution
LifeSPARC
Depression & Heart Failure
Next-Generation HLM

↑
Operational Excellence
Working Capital
Supply Chain
Working Together

We enter 2020 committed to expanding our role as a medical device innovator, so that we can continue to provide hope for patients and their families.

dynamics, significantly increased the amount of time and funding that would be required to bring the product to market. Ceasing the TMVR program will free up approximately \$20 million a year, much of which we will redeploy to our Neuromodulation business, particularly to investments in DTD.

While we have narrowed our focus by exiting our efforts in TMVR, we are continuing to invest in research and development at one of the highest rates in the industry in order to advance our programs and develop more meaningful and innovative technology. Our commitment to Quality and R&D is unwavering, enabling us to provide next-generation devices and technology to the patients we serve.

3T Heater-Cooler® In 2019, we settled the majority of the 3T Heater-Cooler cases, and we are now working diligently on reducing the resulting debt. On February 25, 2020, LivaNova received a 510(k) clearance that will address issues contained in the 2015 3T Warning Letter, along with design changes that further mitigate the potential risk of aerosolization.

Financial Infrastructure We also improved our financial systems by remediating two material weaknesses in internal controls over financial reporting, which were identified in 2018. While there were no material misstatements in our consolidated financial statements, we have addressed the issues through software implementation and improved internal control processes. We will remain vigilant to continuously strengthen our systems and processes and prevent future issues.

Driven by our Mission

In 2019, we launched our Mission, Values and Pillars (MVP) to unite LivaNova employees around a strong mission statement, our embedded values and strategic pillars. The MVP defines who LivaNova is as an organization, demonstrates how we

achieve success and guides what we deliver. This platform creates a stronger connection between our company beliefs and our business goals, generating stronger employee engagement and driving future success.

Focus on 2020

We believe our growth will trend upward. Our implementation of new systems and processes is transforming the company. We are beginning to see results in several areas, such as nine straight quarters of growth in our Europe region and a steady improvement in our gross margin. We remain optimistic about our long-term growth potential and recognize that this success begins with the execution of our 2020 goals. We are stronger and better positioned to deliver consistent growth, increase operating margins through continued gross margin expansion and improve free cash flow while executing the pipeline.

We enter 2020 committed to expanding our role as a medical device innovator, so that we can continue to provide hope for patients and their families. On behalf of LivaNova, our Board of Directors and our nearly 4,000 colleagues around the world who are all united in this mission, I would like to express my sincere appreciation for your investment and for your continued trust and support in our journey. I look forward to the upcoming year and all that we can achieve together.



Damien McDonald
Chief Executive Officer, LivaNova



(1) Excluding the impact of the Canadian distribution agreement

Our MVP: Mission, Values and Pillars

Our mission is who we are, our values are how we achieve and our pillars are what we deliver. All guide and unite us in our commitment.

Mission

At LivaNova, we unite to provide hope for patients and their families through innovative medical technologies, delivering life-changing improvements for both the Head and Heart.

Values

Patients First

Our shared purpose is to improve the lives of patients.

Meaningful Innovation

We develop novel products and therapies to address multiple disease states.

Act with Agility

We challenge ourselves to continuously improve and act nimbly.

Commitment to Quality and Integrity

We dedicate ourselves to high quality and integrity in everything we do.

Collaborative Culture

We value diversity of thought and our collective strength as a team.

Pillars

GROWTH

- Drive demand
- Build pipeline
- Expand portfolio

PROFITABILITY

- Build better
- Spend better
- Price better

TALENT

- Attract
- Retain
- Develop

CULTURE

- Continuous Improvement
- Discipline and Accountability
- Teamwork

Neuromodulation From our highly successful VNS Therapy System for drug-resistant epilepsy (DRE) to the clinical development of neuromodulation solutions for difficult-to-treat depression, heart failure and obstructive sleep apnea, we are committed to offering new hope for patients worldwide.

VNS Therapy

Drug-Resistant Epilepsy

LivaNova pioneered the game-changing VNS Therapy System, and today it is the number-one implantable device for DRE. We see significant opportunity to provide patients with more seizure-free moments.

Global Opportunity

50 million

estimated epilepsy patients worldwide, roughly one-third of whom are drug resistant^{1,2}

LivaNova Leadership

25+ years

years of VNS Therapy leadership

LivaNova Experience

120K+

epilepsy patients implanted to date, including ~30K children

VNS Therapy Benefits for DRE Include:


- Seizure reduction that improves over time³
- Improved quality of life⁴
- Decreased healthcare costs⁵
- Decreased seizure severity/postictal period⁶
- Diminished side effects over time^{7,8}
- Increased treatment adherence

International Growth in Neuromodulation⁹



Bella
VNS Therapy Patient,
Drug-Resistant Epilepsy

Diagnosed at 18 months old, Bella tried many medications that failed to treat her epilepsy. VNS Therapy opened her world by reducing her number of seizures and her recovery time. Now thriving in school and in life, Bella is working to achieve her dream of being valedictorian.



(1) World Health Organization, Epilepsy Fact Sheet, 2019
 (2) Chen Z, et al. JAMA Neurol 2018 Mar 1;75(3):279-286
 (3) Elliott RE, et al. Epilepsy Behav 2011;20(3):478-483
 (4) Klinkenberg S, et al. Clin Neurol Neurosurg 2012;114(4):336-340

(5) Helmers SL, et al. Epilepsy Behav 2011;22(2):370-375
 (6) Data on file, LivaNova, Inc. Houston, TX
 (7) Morris GL III, Mueller WM. Neurology 1999;53(7):1731-1735
 (8) Ben-Menachem E. J Clin Neurophysiol 2001;18(5):415-418
 (9) Constant-currency sales growth, which eliminates the effects of foreign currency fluctuations.

Future Growth Driver

Difficult-to-Treat Depression

LivaNova is developing clinical evidence for VNS Therapy for difficult-to-treat depression (DTD), an area of significant unmet need. We are proud to have begun the RECOVER clinical study in 2019, an important milestone in bringing this therapy to market.

Difficult-to-Treat Depression

4 million

estimated patients with difficult-to-treat depression in the U.S. alone¹

Protocol Approved and Enrollment Begins in the RECOVER Clinical Study

Within weeks of protocol approval, the first patient was enrolled in the RECOVER clinical study, which will determine whether active VNS Therapy treatment is superior to no stimulation in reducing baseline depressive symptom severity. The study framework includes the possibility to extend to a prospective longitudinal study.

Research Collaboration with Verily to Gain New Insights

Through our collaboration with Verily, RECOVER sites can offer patients a Verily smart watch and app to capture additional health data to advance the understanding of depressive episodes and quality of life.

SYMMETRY™ is the first and only FDA-approved implantable device specifically designed for DTD.



Michael

VNS Therapy Patient, DTD

Michael is an ER doctor who suffered from depression despite having tried many medications. VNS Therapy helped him gain control of his depression and rediscover joy in his life.



(1) LivaNova internal estimate based on: U.S. Census Bureau adult population estimate in 2018; Hasin DS, et al., JAMA Psychiatry, 2018; and Amos TB, et al., J Clin Psychiatry, 2018. (2) Card Fail Rev. 2017 Apr; 3(1): 7-11. (3) World Health Organization. Global surveillance, prevention and control of Chronic Respiratory Diseases. A comprehensive approach. 2007.

Future Growth Drivers

Heart Failure & Obstructive Sleep Apnea

We are also applying our VNS Therapy technology leadership to explore an exciting opportunity in heart failure through our ANTHEM-HFrEF U.S. pivotal study. Our investigational hypoglossal nerve stimulation (HGNS) device also shows promise in treating obstructive sleep apnea.


Heart Failure

25 million+

Heart Failure Patients Worldwide²

ANTHEM-HFrEF Pivotal Study

In this pivotal study, we are evaluating the long-term benefits of Autonomic Regulation Therapy (ART) using VNS Therapy through our VITARIA® System to treat patients with chronic, symptomatic heart failure with reduced ejection fraction (HFrEF).



Obstructive Sleep Apnea (OSA)

100 million+

people worldwide suffer from OSA³



OSA is a serious condition where the airway closes during sleep, depriving the brain of oxygen. Our HGNS device restores muscle tone to the tongue, opening the airway while a patient is sleeping.

Benefits of HGNS:

Freedom to sleep without CPAP masks and hoses

A simple procedure, minimally invasive and completely reversible

Minimal side effects that do not affect speech or swallowing

Cardiovascular LivaNova is a strong leader in cardiopulmonary support and cardiac surgery. We bring decades of market and technology leadership to help perfusionists, surgeons and cardiologists improve outcomes for their patients. We are committed to advancing our leadership and helping patients around the world.

LivaNova Devices

50%+

Our devices are used in more than half of all open-heart surgeries worldwide

Heart-Lung Machines

40+ years

Our heart-lung machines have led the market for more than four decades

Cardiopulmonary Bypass

#1

We are the recognized leader in cardiopulmonary bypass support across the world



Exciting New Technology

Advanced Circulatory Support

Our new LifeSPARC Advanced Circulatory Support (ACS) system builds on 20 years of life support experience to bring next-generation innovation to life. LifeSPARC launched ahead of schedule in 2019, and we expect to see continued growth in 2020 and beyond.

Next-Generation Portability and Power

LifeSPARC is a compact pump and controller for temporary cardiopulmonary bypass. The simple, versatile system enables hospitals to support more patients in more places.

\$1B+
global market

4 Types of Ready-to-Deploy Kits

Each kit is designed to support emergent rescue patients with diverse cannulation strategies for ACS.



Decades of Market Leadership Cardiopulmonary and Heart Valve Technologies

S5®: The Fifth Generation of Heart-Lung Machine (HLM) Innovation

Designed for years of demanding performance, our modular HLM sets the bar for functionality, flexibility and quality. Easy component exchanges and more configuration options make the S5 the world's leading perfusion system.

70%
estimated
HLM global
market share



Our world-leading portfolio of cardiopulmonary technologies positions LivaNova to make a meaningful difference in cardiac surgery. Plus, our Perceval® heart valve continues to be an innovative solution for a wide range of surgical approaches.

Inspire: A New Standard for Oxygenators

Inspire oxygenators have achieved record global adoption, while helping reduce the physiological impact of critical cardiac surgery for patients every day all over the world.



1 million+
patients
served



Perceval: The Biological Valve of Choice in Aortic Valve Replacement

Perceval has 10 years of clinical data, demonstrating strong performance in durability and outcomes. An absence of explants and low rate of paravalvular leak in long-term data reaffirms its position as a trusted platform.

10+ years
of successful use




Maria, Perceval patient

One of the first patients to receive a Perceval valve, Maria benefitted from the innovative sutureless surgical procedure to address her heart valve issues.


LivaNova: 2019 at a Glance

2019 Sales by Geography



| | |
|---------------|--------|
| United States | \$546M |
| Europe | \$223M |
| Rest of World | \$315M |

2019 Sales by Business



| | |
|-----------------|--------|
| Cardiovascular | \$657M |
| Neuromodulation | \$425M |

Investing in innovation:

14%
of sales dedicated
to R&D¹

1st

patients implanted in RECOVER
depression study

A landmark achievement, 10 years in the making

9 consecutive
quarters of growth
in Europe²

>25%
organic growth
in Advanced
Circulatory Support³

2019 Net Sales
\$1.1 Billion

~70%
Adjusted Gross Margin¹

+150bps
expansion over prior year

>100 countries
helping patients in more
than 100 countries

~4,000
employees around
the world

*Note: Numbers may not add up precisely due to rounding.

(1) Adjusted financial measures are non-GAAP measures and exclude specified items as described and reconciled in the "Reconciliation of GAAP to non-GAAP Financial Measures."

(2) Constant-currency sales growth, which eliminates the effects of foreign currency fluctuations.

(3) 2019 organic growth in Advanced Circulatory Support includes ~\$6 million in sales from TandemLife in the first quarter of 2018, prior to LivaNova's acquisition of TandemLife.

Reconciliation of GAAP to Non-GAAP Financial Measures – Twelve Months Ended December 31, 2019 (Unaudited)

| | GAAP Financial Measures | Merger and Integration Expenses (A) | Restructuring Expenses (B) | Depreciation and Amortization Expenses (C) | Impairments (D) | Product Remediation Expenses (E) | Acquisition Costs (F) | Non-recurring Legal, Contingent Consideration and Other Reserves (G) | Stock-based Compensation Costs (H) | Certain Tax Adjustments (I) | Certain Interest Adjustments (J) | Adjusted Financial Measures |
|--|-------------------------|-------------------------------------|----------------------------|--|-----------------|----------------------------------|-----------------------|--|------------------------------------|-----------------------------|----------------------------------|-----------------------------|
| Gross margin | 68.7% | —% | —% | 0.2% | —% | 1.5% | —% | (0.9)% | 0.1% | —% | —% | 69.6% |
| Research and development as a percent of net sales | 13.8% | —% | —% | —% | (0.3)% | —% | 0.2% | 1.0% | (0.5)% | —% | —% | 14.1% |

GAAP results for the twelve months ended December 31, 2019 include:

- (A) Merger and integration expenses related to our legacy companies and recent acquisitions
 (B) Restructuring expenses related to organizational changes
 (C) Includes depreciation and amortization associated with purchase price accounting
 (D) Impairment of Transcatheter Mitral Valve Replacement goodwill, intangible assets and other long-lived assets and Obstructive Sleep Apnea intangible assets and other long-lived assets
 (E) Costs related to the 3T Heater-Cooler remediation plan
 (F) Costs related to acquisitions
 (G) 3T Heater-Cooler litigation provision, 3T insurance recovery, legal expenses primarily related to 3T Heater-Cooler defense, settlements and other matters, remeasurement of contingent consideration related to acquisitions and AR reserves
 (H) Non-cash expenses associated with stock-based compensation costs
 (I) Primarily relates to discrete tax items and the tax impact of intercompany transactions
 (J) Primarily relates to intellectual property migration, interest related to 3T Heater-Cooler litigation settlement and other non-recurring impacts to interest expense

Reconciliation of GAAP to Non-GAAP Financial Measures – Twelve Months Ended December 31, 2018 (Unaudited)

| | GAAP Financial Measures | Merger and Integration Expenses (A) | Restructuring Expenses (B) | Depreciation and Amortization Expenses (C) | Product Remediation Expenses (D) | Acquisition Costs (E) | CRM Disposal Costs (F) | Non-recurring Legal and Contingent Consideration (G) | Stock-based Compensation Costs (H) | Certain Tax Adjustments (I) | Certain Interest Adjustments (J) | Adjusted Financial Measures |
|--------------|-------------------------|-------------------------------------|----------------------------|--|----------------------------------|-----------------------|------------------------|--|------------------------------------|-----------------------------|----------------------------------|-----------------------------|
| Gross margin | 66.4% | —% | —% | 1.0% | 1.0% | —% | —% | (0.3)% | 0.1% | —% | —% | 68.1% |

GAAP results for the twelve months ended December 31, 2018 include:

- (A) Merger and integration expenses related to our legacy companies and recent acquisitions
 (B) Restructuring expenses related to organizational changes
 (C) Includes depreciation and amortization associated with purchase price accounting
 (D) Costs related to the 3T Heater-Cooler remediation plan
 (E) Costs related to acquisitions
 (F) Corporate costs incurred to divest of the CRM business not attributable to discontinued operations
 (G) 3T Heater-Cooler litigation provision, legal expenses primarily related to 3T Heater-Cooler defense, settlements and other matters, remeasurement of contingent consideration related to acquisitions and AR reserves
 (H) Non-cash expenses associated with stock-based compensation costs
 (I) Primarily relates to discrete tax items and the tax impact of intercompany transactions
 (J) Primarily relates to intellectual property migration and other non-recurring impacts to interest expense

Neuromodulation Net Sales: Comparison of Actual Results to Constant-Currency (Unaudited)

(U.S. dollars in millions)

| | Twelve months ended December 31, | | % Change at Actual Currency Rates | % Change at Constant-Currency Rates ¹ |
|---------------------------------|----------------------------------|-------|-----------------------------------|--|
| | 2019 | 2018 | | |
| U.S. | 335.3 | 349.0 | (3.9%) | (3.9%) |
| Europe | 46.3 | 42.4 | 9.0% | 15.0% |
| Rest of World | 43.0 | 31.6 | 36.1% | 39.7% |
| Total Neuromodulation Net Sales | 424.5 | 423.0 | 0.4% | 1.2% |

(1) Management believes that referring to comparable, constant-currency growth is the most useful way to evaluate the sales performance of LivaNova and to compare the sales performance of current periods to prior periods on a consistent basis. Constant-currency growth, a non-GAAP financial measure, measures the change in sales between current and prior-year periods using average exchange rates in effect during the applicable prior-year period.

*Note: Numbers in the above tables may not add up precisely due to rounding.

Board of Directors

Daniel Moore

Chairman of the Board, LivaNova. Former Chief Executive Officer and member of the board of directors of Cyberonics.

Damien McDonald

Chief Executive Officer, LivaNova. Previously served as Chief Operating Officer at LivaNova. Former Group Executive and Corporate Vice President at Danaher Corporation.

Francesco Bianchi

Former member of the board of directors of Sorin. Former General Manager and Head of the M&A and Corporate Finance Division at Bankers Trust.

Stacy Enxing Seng

Former President of Covidien Vascular Therapies and former President of Covidien Peripheral Vascular.

William Kozy

Former Executive Vice President and Chief Operating Officer at Becton, Dickinson and Company (BD).

Hugh Morrison

Former Chairman of the board of directors for Cyberonics. Former Managing Director at Callahan Advisors.

Alfred J. Novak

Former member of the board of directors of Cyberonics. Former Chairman and Chief Executive Officer of OrbusNeich Medical Technology Company.

Sharon O’Kane

Entrepreneur in Residence at University College Dublin. Co-Founder and former Chief Scientific Officer and Executive Director of Renovo Group.

Arthur L. Rosenthal

Former member of the board of directors of Cyberonics. Co-Founder and former Chief Executive Officer of gEyeCue.

Andrea L. Saia

Former executive at Novartis, including roles as President and Chief Executive Officer of the CIBAVision subsidiary and Global Head of the Vision Care Division.

Executive Management

Damien McDonald

Chief Executive Officer

Thad Huston

Chief Financial Officer

Keyna Skeffington

Senior Vice President, General Counsel

Stephanie Bolton

President, Europe

Paul Buckman

President, North America

Matthew Dodds

Senior Vice President, Corporate Development

Marco Dolci

Head of Global Operations and R&D

Trui Hebbelink

Chief Human Resources Officer

Roy Khoury

President, International; Senior Vice President, Global Strategic Marketing

Ryan Miller

Vice President, Strategy

Bryan Olin, PhD

Senior Vice President, Clinical, Quality Assurance and Regulatory Affairs

Key Worldwide Locations

Europe

LivaNova PLC (Headquarters)
20 Eastbourne Terrace
London, W2 6LG
United Kingdom

Paris, France

Milan, Italy

Mirandola, Italy

Saluggia, Italy

Munich, Germany

North America

Houston, Texas

Arvada, Colorado

Pittsburgh, Pennsylvania

Vancouver, Canada

Latin and South America

San Paolo, Brazil

Dominican Republic

Asia

Shanghai, China

Tokyo, Japan

Additional Information

Additional information about LivaNova, including news and financial data, is available by visiting the company’s website: www.livanova.com

Any forward-looking statements are subject to risks and uncertainties such as those described in our periodic reports on file with the U.S. Securities and Exchange Commission. Actual results may differ materially from anticipated results. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements.

This report is printed on FSC® Certified paper, SFI® Certified Sourcing and Rainforest Alliance Certified™. Featuring 10% post-consumer recycled content and certified fiber.



LivaNova
Health innovation that matters